232 related articles for article (PubMed ID: 26378777)
1. Industry perspectives on biomarker qualification.
Lavezzari G; Womack AW
Clin Pharmacol Ther; 2016 Feb; 99(2):208-13. PubMed ID: 26378777
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on statistical strategies for the regulatory biomarker qualification process.
Hendrix SB; Mogg R; Wang SJ; Chakravarty A; Romero K; Dickson SP; Sauer JM; McShane LM
Biomark Med; 2021 Jun; 15(9):669-684. PubMed ID: 34037457
[TBL] [Abstract][Full Text] [Related]
3. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.
Amur S; LaVange L; Zineh I; Buckman-Garner S; Woodcock J
Clin Pharmacol Ther; 2015 Jul; 98(1):34-46. PubMed ID: 25868461
[TBL] [Abstract][Full Text] [Related]
4. Preclinical biomarker qualification.
Sauer JM; Porter AC;
Exp Biol Med (Maywood); 2018 Feb; 243(3):222-227. PubMed ID: 29171289
[TBL] [Abstract][Full Text] [Related]
5. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
[TBL] [Abstract][Full Text] [Related]
6. A prototypical process for creating evidentiary standards for biomarkers and diagnostics.
Altar CA; Amakye D; Bounos D; Bloom J; Clack G; Dean R; Devanarayan V; Fu D; Furlong S; Hinman L; Girman C; Lathia C; Lesko L; Madani S; Mayne J; Meyer J; Raunig D; Sager P; Williams SA; Wong P; Zerba K
Clin Pharmacol Ther; 2008 Feb; 83(2):368-71. PubMed ID: 18091762
[TBL] [Abstract][Full Text] [Related]
7. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
Sistare FD; DeGeorge JJ
Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of drug-induced acute kidney injury: a regulatory perspective.
Blank M; Thompson A; Hausner E; Rouse R
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):929-936. PubMed ID: 30099912
[TBL] [Abstract][Full Text] [Related]
9. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium.
Miller BE; Tal-Singer R; Rennard SI; Furtwaengler A; Leidy N; Lowings M; Martin UJ; Martin TR; Merrill DD; Snyder J; Walsh J; Mannino DM
Am J Respir Crit Care Med; 2016 Mar; 193(6):607-13. PubMed ID: 26745765
[TBL] [Abstract][Full Text] [Related]
10. Biomarker qualification pilot process at the US Food and Drug Administration.
Goodsaid F; Frueh F
AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
[TBL] [Abstract][Full Text] [Related]
11. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium.
Dieterle F; Sistare F; Goodsaid F; Papaluca M; Ozer JS; Webb CP; Baer W; Senagore A; Schipper MJ; Vonderscher J; Sultana S; Gerhold DL; Phillips JA; Maurer G; Carl K; Laurie D; Harpur E; Sonee M; Ennulat D; Holder D; Andrews-Cleavenger D; Gu YZ; Thompson KL; Goering PL; Vidal JM; Abadie E; Maciulaitis R; Jacobson-Kram D; Defelice AF; Hausner EA; Blank M; Thompson A; Harlow P; Throckmorton D; Xiao S; Xu N; Taylor W; Vamvakas S; Flamion B; Lima BS; Kasper P; Pasanen M; Prasad K; Troth S; Bounous D; Robinson-Gravatt D; Betton G; Davis MA; Akunda J; McDuffie JE; Suter L; Obert L; Guffroy M; Pinches M; Jayadev S; Blomme EA; Beushausen SA; Barlow VG; Collins N; Waring J; Honor D; Snook S; Lee J; Rossi P; Walker E; Mattes W
Nat Biotechnol; 2010 May; 28(5):455-62. PubMed ID: 20458315
[TBL] [Abstract][Full Text] [Related]
12. Biomarker qualification via public-private partnerships.
Eck SL; Paul SM
Clin Pharmacol Ther; 2010 Jan; 87(1):21-3. PubMed ID: 20019697
[TBL] [Abstract][Full Text] [Related]
13. Current and future state of FDA-CMS parallel reviews.
Messner DA; Tunis SR
Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
[TBL] [Abstract][Full Text] [Related]
14. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
[TBL] [Abstract][Full Text] [Related]
15. What evidence do we need for biomarker qualification?
Leptak C; Menetski JP; Wagner JA; Aubrecht J; Brady L; Brumfield M; Chin WW; Hoffmann S; Kelloff G; Lavezzari G; Ranganathan R; Sauer JM; Sistare FD; Zabka T; Wholley D
Sci Transl Med; 2017 Nov; 9(417):. PubMed ID: 29167393
[TBL] [Abstract][Full Text] [Related]
16. Exclusive Drug Labeling Rights as a New Incentive for Contribution to a Communal Biomarker Resource.
Shore D
Am J Law Med; 2018 Nov; 44(4):607-626. PubMed ID: 30802165
[TBL] [Abstract][Full Text] [Related]
17. Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice.
Mattes WB; Goodsaid F
Exp Biol Med (Maywood); 2018 Feb; 243(3):256-261. PubMed ID: 29110507
[TBL] [Abstract][Full Text] [Related]
18. Market watch: upcoming market catalysts in Q4 2010.
Rosenthal J
Nat Rev Drug Discov; 2010 Oct; 9(10):755. PubMed ID: 20885399
[No Abstract] [Full Text] [Related]
19. Evaluating the Use of KIM-1 in Drug Development and Research Following FDA Qualification.
Chen R; Sanyal S; Thompson A; Ix JH; Haskins K; Muldowney L; Amur S
Clin Pharmacol Ther; 2018 Dec; 104(6):1175-1181. PubMed ID: 29761868
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers: a US FDA effort.
Hong H; Goodsaid F; Shi L; Tong W
Biomark Med; 2010 Apr; 4(2):215-25. PubMed ID: 20406066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
